Neonatal cushingoid syndrome resulting from serial courses of antenatal betamethasone.
BACKGROUND
Antenatal steroid therapy has been shown to induce accelerated pulmonary maturation in preterm fetuses when delivery is imminent. Although this form of therapy has been used for 20 years, few studies or case reports have discussed the indications for or complications of retreatment, especially when more than two courses of steroids have already been given. We report a case of neonatal cushingoid syndrome with hypothalamic-pituitary-adrenal axis suppression following maternal treatment with seven courses of betamethasone.


METHODS
A 31-year-old white woman, gravida 3, para 1, spontaneous abortion 1, presented with a single intrauterine pregnancy at 24 weeks' gestation, a bulging amniotic sac, and repeated cerclage failure. Antenatal betamethasone therapy was begun at 12.5 mg intramuscularly every 12 hours for two doses. Because of cervical dilatation, bulging membranes, and intermittent contractions, the expectation of imminent premature delivery did not diminish over the next 42 days. As the effect of antenatal steroids wanes after 7 days, a course of therapy was administered each week for as long as the threat of preterm delivery remained. Seven courses of betamethasone were given before delivery at 34.5 weeks post-conception age. The 2625-g male neonate appeared cushingoid on physical examination, with basal serum cortisol levels less than 3.3 micrograms/dL.


CONCLUSIONS
Physical findings of the neonate and laboratory investigation of both infant and mother suggested combined hypothalamic-pituitary-adrenal axis suppression. The cushingoid features of the infant demonstrate an undesired and previously unreported complication of an effective antenatal therapy. The unusual variant in this case was that the initial indication for steroid therapy (risk of premature delivery) persisted for 8 weeks after the first dose of betamethasone. It remains unknown how many weekly antenatal steroid courses can be administered before marked fetal adrenal suppression becomes evident. Risk-benefit ratios should be carefully considered before each retreatment.
Bradley
B S
BS
Department of Pediatrics, Henry Ford Hospital, Detroit, Michigan.
Kumar
S P
SP
Mehta
P N
PN
Ezhuthachan
S G
SG
D000328:Adult; D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D003480:Cushing Syndrome / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011247:Pregnancy; D011295:Prenatal Care
D001623:Betamethasone